Dysregulation of Serotonin Signaling between Gut Microbiota and Gut Enterochromaffin Cells Triggers Irritable Bowel Syndrome
Background
Irritable bowel syndrome (IBS) is a representative gut-brain interaction disorder that causes abdominal pain, bloating, and bowel dysfunction, reducing quality of life. While affecting a significant portion of the global population, its molecular pathogenesis has remained unclear. To date, clinical diagnosis has relied on the Rome criteria, which are symptom-based surveys. Treatments have also been limited to non-mechanistic prescriptions focused on temporarily alleviating individual symptoms such as diarrhea or constipation.
This symptom-oriented approach fails to explain the vastly different treatment responses seen in patients. This is also why most drugs show limited efficacy in only certain groups or fail to prevent recurrence. In the absence of fundamental biological targets and biomarkers, establishing a system of precise classification and targeted therapy based on molecular mechanisms has been identified as an urgent task in gastrointestinal disease research.
Key Findings
The intestinal serotonin (5-hydroxytriumamine, hereafter 5-HT) signaling axis has been proposed as a central integrative mechanism connecting gut microbiota, enterochromaffin (EC) cells, the enteric nervous system, and the mucosal immune system. This finding comprehensively elucidates the molecular communication process between microbial signals and the host nervous system, noting that over 90% of human 5-HT is secreted by EC cells in the intestinal mucosa.
5-HT secretion from EC cells is precisely regulated by metabolic signals induced by gut microbiota. Metabolites produced as microbes break down tryptophan, along with short-chain fatty acids (SCFA) such as acetate, propionate, and butyrate, and secondary bile acid signals, directly alter the expression and epigenetic state of tryptophan hydroxylase 1 (TPH1), a serotonin synthesis enzyme. When microbial ecosystem imbalance occurs, the regulatory balance of TPH1 is disrupted, causing abnormal amounts of 5-HT to flood the mucosal interior.
Excessively secreted 5-HT immediately disrupts the intestinal mucosal neuroimmune network. A chain reaction was confirmed where it stimulates mast cells to secrete histamine and proteases and induces pro-inflammatory polarization of macrophages, triggering local neurogenic inflammation. This signal ascends to the central nervous system via vagal afferent fibers, regulating blood-brain barrier permeability and causing widespread changes in the brain's neurotransmitter networks. This essentially proves at a molecular level the pathway through which serotonin imbalance starting in the gut leads to systemic nervous system symptoms.
The researchers presented a molecular subtype classification model based on the serotonin axis, known as serotonergic endotyping. This method combines genetic polymorphisms of the serotonin transporter gene (SLC6A4) and TPH1 with single-cell transcriptomics and spatial metabolomics. This allows for the precise segmentation of a patient's biological cause of disease, moving beyond simple bowel habit classifications (diarrhea-predominant, constipation-predominant, mixed-type).
In evaluating therapeutic strategies, the study highlighted the pros and cons of next-generation engineering technologies. Engineered probiotic chassis modified with customized genomes, CRISPR-based microbial gene editing, and AI-designed nanomedicines have shown promising preclinical proof-of-concept results in precisely targeting the microbiota-5-HT pathway. However, the study noted that additional procedures are required to verify long-term safety and delivery efficiency compared to existing small-molecule inhibitors or dietary interventions before these advanced techniques can be used in actual patients.
Significance and Outlook
This research redefines IBS not merely as a functional abdominal pain syndrome, but as a metabolic and neuroimmune disorder arising from the collapse of the microbial serotonin ecosystem. It is evaluated as providing the theoretical foundation to shift the clinical paradigm from symptom alleviation to mechanism-centered precision medicine.
There are still significant practical barriers to overcome. Work is required to determine whether changes in gut microbial metabolites are the cause of 5-HT imbalance or a secondary consequence of changes in intestinal motility. Since microbial diversity varies extremely between individuals, translational research must follow to confirm whether the molecular axes proven in animal models are identically reproduced in human clinical settings.
Irritable bowel syndrome (IBS) is a common, often disabling disorder of gut-brain interaction whose molecular basis remains incompletely defined, leaving diagnosis largely symptom-based and treatment largely non-mechanistic. We argue that the serotonin (5-hydroxytryptamine; hereafter 5-HT, the primary term used throughout, with "serotonin" retained in less technical contexts) signalling axis-positioned at the interface of the gut microbiota, enterochromaffin (EC) cells, enteric neurons, and the mucosal immune system-is a central, unifying integrator of IBS pathophysiology, and that reframing IBS around this axis offers a route toward mechanism-based subtyping and therapy. We first synthesise how microbiota-driven tryptophan metabolism, short-chain fatty acid and secondary bile acid signalling, and epigenetic regulation of tryptophan hydroxylase 1 (TPH1) shape EC-cell serotonin output, before examining the neuroimmune consequences of dysregulated serotonin secretion-mast cell activation, macrophage polarisation, neurogenic inflammation-and the microbiota-serotonin-gut-brain connectome linking vagal afferent signalling, blood-brain barrier permeability, and central neurotransmitter networks. We then discuss molecular stratification of IBS subtypes through serotonergic endotyping-incorporating SLC6A4 and TPH1 polymorphisms, single-cell transcriptomics, and spatial metabolomics-and critically evaluate next-generation therapeutic strategies, including engineered probiotic chassis, CRISPR-mediated microbial editing, and AI-guided nanomedicine, distinguishing proof-of-concept findings from clinically validated approaches. We conclude that reconceptualising IBS as a disorder of disrupted microbial serotonergic ecosystems, rather than a purely symptom-defined syndrome, offers a coherent and testable framework for biomarker discovery and precision, mechanism-directed therapy, while highlighting the causal-directionality and clinical-translation gaps that must be closed before
In clinical settings, the development of companion diagnostic panels combining serotonin transporter and synthesis enzyme gene testing with metabolite analysis is expected. Moving away from the method of prescribing 5-HT3 receptor antagonists uniformly to diarrhea-predominant patients, it will be possible to pre-screen patient groups showing TPH1 epigenetic modifications or specific metabolite abnormalities to proceed with customized medication. Industrially, it provides clear molecular targets for the development of next-generation microbiome therapeutics that directly regulate intestinal tryptophan metabolic pathways and pipelines for targeted live biotherapeutic products.